• Clinical Trials

    __00.png Call 1-877-547-1750

     

    Clinical trials are the final step in a long process that often begins in the lab. Many cancer treatments used today are results of past clinical trials. Clinical trials are key to developing new methods to prevent, detect, and treat cancer. It is through clinical trials that researchers can determine whether new treatments are safe and effective and work better than current treatments. When you take part in a clinical trial, you add to our knowledge about cancer and help improve cancer care. For more information about clinical trials, click this link provided by the National Cancer Institute.

    The Bassett Cancer Institute has been providing access to cutting edge treatments in a convenient, local setting for over 40 years. Bassett's membership in the Eastern Cooperative Oncology Group (ECOG) allows access to numerous clinical trials through the Clinical Trials Support Unit (CTSU), funded by The National Institutes of Health (NIH) and The National Cancer Institutes (NCI).

    ACT (About Clinical Trials) is a website to help empower people to understand cancer clinical trials and discuss this option with their doctors and loved ones. This unique resource features unscripted interviews with clinical trial participants, doctors, patient rights advocates, and others. Their honest stories and the information on this site will help you ACT toward having informed discussions with those committed to your care.

    For more information regarding ACT, please follow this link and explore.

    Learn more about Bassett's Cancer Clinical Trials program by clicking here, where patients tell their stories.

    Blood Disorders

    Connect® MDS/AML Disease Registry

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT01688011

    (Project 2076) 
    Eric Bravin, M.D. 
    Trial Contact Information: 
    Diana Crean diana.crean@bassett.org 607-547-3073 
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    E1A11: Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Myeloma (ENDURANCE)

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT01863550

    (Project 1086) 
    Eric Bravin, M.D. 
    Trial Contact Information: 
    Diana Crean diana.crean@bassett.org 607-547-3073 
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    Breast Cancer

    NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT01872975

    (Project 1056)
    Joy Anderson, M.D.
    Trial Contact Information:                                   
    Diana Crean diana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    PALLAS: PALbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02513394

    (Project 2039) 
    Eric Bravin, M.D.
    Trial Contact Information:                                   
    Diana Crean diana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02750826

    (Project 2075) 
    Eric Bravin, M.D.
    Trial Contact Information:                                   
    Diana Crean diana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    A011502: A Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
    NCT02927249

    (Project 2073) 
    Eric Bravin, M.D.
    Trial Contact Information:                                   
    Diana Crean diana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

    Colon Cancer

    A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02912559

    (Project 2082) 
    Eric Bravin, M.D. 
    Trial Contact Information: 
    Diana Crean diana.crean@bassett.org 607-547-3073 
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

    Lung Cancer

    A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02194738

    (Project 1083)
    Eric Bravin, M.D.
    Trial Contact Information:
    Diana Crean diana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein 

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02201992

    (Project 1085)
    Eric Bravin, M.D.
    Trial Contact Information:
    Diana Crean diana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02193282

    (Project 1084)
    Eric Bravin, M.D.
    Trial Contact Information:
    Diana Crean diana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02595944

    (Project 2043) 
    Eric Bravin, M.D. 
    Trial Contact Information: 
    Diana Crean diana.crean@bassett.org 607-547-3073 
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    S1400: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer 
    (Lung-Map) 

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02154490

    (Project 2000)
    Eric Bravin, M.D.
    Trial Contact Information:
    Diana Crean diana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

    Melanoma

    EA6134: A Randomized Phase III Trial of Dabrafenib +  Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02224781

    (Project 2020)
    Eric Bravin, M.D.
    Trial Contact Information:
    Diana Creandiana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

     

    EA6141: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02339571

    (Project 2021)
    Eric Bravin, M.D.
    Trial Contact Information:
    Diana Creandiana.crean@bassett.org 607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

    Pancreatic

    CanStem111P: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02993731

    (Project 2076) 
    Eric Bravin, M.D. 
    Trial Contact Information: 
    Diana Creandiana.crean@bassett.org 607-547-3073 
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328

    Prostate Cancer

    RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial

    For more information regarding this trial, visit the ClinicalTrials.gov Identifier:

    NCT02673190

    (Project 1090)
    Timothy Korytko, M.D.
    Trial Contact Information:
    Diana Crean diana.crean@bassett.org607-547-3073
    Tari Miller, RN tari.miller@bassett.org 607-547-6373
    Diana Gaetano, RN diana.gaetano@bassett.org 607-547-3328